GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Accounts Receivable

Orphazyme AS (CHIX:ORPHAC) Accounts Receivable : kr23.77 Mil (As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Orphazyme AS's accounts receivables for the quarter that ended in Jun. 2022 was kr23.77 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Orphazyme AS's Net-Net Working Capital per share for the quarter that ended in Jun. 2022 was kr1,471.87.


Orphazyme AS Accounts Receivable Historical Data

The historical data trend for Orphazyme AS's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Accounts Receivable Chart

Orphazyme AS Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Accounts Receivable
Get a 7-Day Free Trial - - - - 29.27

Orphazyme AS Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 26.30 29.27 23.77

Orphazyme AS Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Orphazyme AS Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Orphazyme AS's Days Sales Outstanding for the quarter that ended in Jun. 2022 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=23.765/0*91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Orphazyme AS's accounts receivable are only considered to be worth 75% of book value:

Orphazyme AS's Net-Net Working Capital Per Share for the quarter that ended in Jun. 2022 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(49.532+0.75 * 23.765+0.5 * 0-15.384
-0-0)/0.03531
=1,471.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Orphazyme AS Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Orphazyme AS's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Orphazyme AS (CHIX:ORPHAC) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines